Alvotech
Manufacturing · Iceland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
15-19 Saemundargata, Reykjavik, Höfuðbor...Phone Number
+354 4224500Website
www.alvotech.comRevenue
$492 MillionStock Symbol
ALVOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patientsRead more
Alvotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alvotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Alvotech, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Alvotech
Website visits: Recent activity has been detected on your website
Check if Alvotech has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Alvotech has new funding data
Earning: See what the market has to say on Alvotech recently announced quarterly report
Click to see if Alvotech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Alvotech launches new products
Check out if Alvotech is spiking on competitors!
Recommended Actions
Find VP level buyers at Alvotech
Find more new buyers
Company Profile Activity
Activity Insights
Alvotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alvotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alvotech.
Alvotech financials insights
Gather financial insights about Alvotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$300M
2021
Share Placement
$35M
2022
Multiple Rounds
$136M
2023
Debt
$100M
2026
Multiple Rounds
$357.2M
Alvotech Tech Stack
A closer look at the technologies used by Alvotech
Most Recent Scoops
Funding
Funding
Person-Based
Pharmaceuticals
Open Position
Open Position
Open Position
Alvotech News & Media
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposedAlvotech Q2 Earnings Call Highlights
Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and prAlvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alvotech
Sign Up For FreeTo access detailed company insights
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditio... Read More
